Value
9.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| Analyst target | 9.0 |
- ▸Attractively valued
VOR · Why this verdict
Why Vor Biopharma (VOR) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Vor Biopharma is a pre-revenue, cash-burning biotech whose value rests on a single pipeline asset (telitacicept) licensed from RemeGen, with large analyst upside offset by below-floor quality and a 63% drawdown.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline is concentrated in a single product, telitacicept, flagged as a high concentration risk. Bear case | Clinical and regulatory progress on telitacicept supports the current valuation over the next 12 months. | ↑Improving |
| CounterA single successful asset can justify a small-cap biotech's valuation, and the analyst target implies the market underprices that outcome. | ||
The company is pre-revenue (quarterly revenue of $0 in all of the last 5 quarters), cash-burning with operating margin at -81.6%, and has a weak Piotroski F-Score of 2/9. Quality breakdown | Cash burn stays within funding capacity and the Piotroski F-Score does not decline further over 12 months. | →Stable |
| CounterPre-revenue biotechs are expected to burn cash, and a current ratio component of 5.0 suggests near-term liquidity is adequate. | ||
Vor depends on RemeGen as its counterparty for telitacicept, a second high-severity concentration risk disclosed in its risk factors. Bear case | The RemeGen relationship stays intact with no adverse change to the licensing terms over 12 months. | ↑Improving |
| CounterLicensing agreements typically include milestone-based terms that align both parties, which limits the likelihood of a unilateral exit. | ||
The $33.93 analyst target is about 85.8% above the $18.26 price, and sentiment is supported by positive news (+0.42) and institutional accumulation. Sentiment breakdown | Price closes part of the 85.8% gap to the $33.93 target as pipeline milestones are met. | ↓Deteriorating |
| CounterWith light analyst coverage the target is dampened, and the stock is down 63% from its 52-week high, so targets may not be reachable. | ||
Risk is elevated: short interest is 16% and implied volatility is 103%, with falling on-balance volume. Risk breakdown | Short interest declines below 10% as pipeline news flow improves. | ↑Improving |
| CounterHigh short interest in a battered biotech can fuel a squeeze on positive data. | ||
The pipeline is concentrated in a single product, telitacicept, flagged as a high concentration risk.
↑ImprovingBear case
- Expectation
- Clinical and regulatory progress on telitacicept supports the current valuation over the next 12 months.
CounterA single successful asset can justify a small-cap biotech's valuation, and the analyst target implies the market underprices that outcome.
The company is pre-revenue (quarterly revenue of $0 in all of the last 5 quarters), cash-burning with operating margin at -81.6%, and has a weak Piotroski F-Score of 2/9.
→StableQuality breakdown
- Expectation
- Cash burn stays within funding capacity and the Piotroski F-Score does not decline further over 12 months.
CounterPre-revenue biotechs are expected to burn cash, and a current ratio component of 5.0 suggests near-term liquidity is adequate.
Vor depends on RemeGen as its counterparty for telitacicept, a second high-severity concentration risk disclosed in its risk factors.
↑ImprovingBear case
- Expectation
- The RemeGen relationship stays intact with no adverse change to the licensing terms over 12 months.
CounterLicensing agreements typically include milestone-based terms that align both parties, which limits the likelihood of a unilateral exit.
The $33.93 analyst target is about 85.8% above the $18.26 price, and sentiment is supported by positive news (+0.42) and institutional accumulation.
↓DeterioratingSentiment breakdown
- Expectation
- Price closes part of the 85.8% gap to the $33.93 target as pipeline milestones are met.
CounterWith light analyst coverage the target is dampened, and the stock is down 63% from its 52-week high, so targets may not be reachable.
Risk is elevated: short interest is 16% and implied volatility is 103%, with falling on-balance volume.
↑ImprovingRisk breakdown
- Expectation
- Short interest declines below 10% as pipeline news flow improves.
CounterHigh short interest in a battered biotech can fuel a squeeze on positive data.
Per-dimension breakdown
Quality
1.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.5 |
| Piotroski F | 2.2 |
- ▸Cash-burning (FCF negative)
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 2/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 7.0 |
| Volume | 5.1 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.2 |
| Analyst rating | 7.9 |
| Price target | 10.0 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 89%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 9.8 |
| quality rank | 5.0 |
| growth rank | 5.0 |
- ▸Attractive P/E vs peers
Technical
0.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.5 |
| 52w position | 0.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 2.6 |
| days to cover | 4.8 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 4.1 |
- ▸High IV: 107%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.3/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 6.0 |
- ▸Earnings in 14 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (6)
- MOMENTUM:7.5>=5.5
- ASYMMETRY:4.5>=1.5
- INSIDER:OK
- 8K:CLEAN
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- EARNINGS_PROXIMITY:14d<=14d (soft)
Reward-to-Risk
4.50
Upside
+64.3%
Downside
14.3%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.1B) below institutional reach
SuitabilitySpeculative — Drawdown -59% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.4 and asymmetric R:R of 4.50.
The strongest dimensions are Value at 9.4, Sentiment at 8.0, and Momentum at 7.5; the weakest are Technical at 0.2, Quality at 1.5, and Risk (lower is worse) at 3.6. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 4.50 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Single Asset Pipeline Concentration
Trip ifA clinical or regulatory setback causes the share price to fall below $16.99, the support level.
- P2Licensor Counterparty Dependence
Trip ifShare of pipeline value tied to RemeGen exceeds 100% of lead-asset revenue potential with any termination notice.
- P3Cash Burn No Revenue
Trip ifOperating margin falls below -120% from the current -81.6%.
- P4Analyst Upside To Target
Trip ifAnalyst target falls below $25 from the current $33.93.
- P5High Short Interest And Volatility
Trip ifShort interest rises above 25% from the current 16%.